Objective: The objective of this report is to evaluate the prevalence and clinico-serological correlations of anti-a-enolase antibody (Ab) in patients with systemic lupus erythematosus (SLE). Methods: Thirty-two untreated patients with SLE and 20 age-and sex-matched healthy controls were evaluated by rheumatologic examinations. The serum levels of anti-a-enolase Ab were measured by an enzyme-linked immunosorbent assay (ELISA). Clinical, biochemical and serological markers of disease activity were measured by standard laboratory procedure. Results: The serum levels of anti-a-enolase Ab in SLE patients were higher significantly than those in healthy controls. Moreover, patients with lupus nephritis displayed significantly higher levels of serum anti-a-enolase Ab than those without renal involvement. The serum anti-a-enolase Ab levels were positively correlated with serum whole IgG and 24-hour urine protein and negatively correlated with serum D-dimer level. Conclusion: These data suggest that anti-a-enolase Ab associates with active renal disease in SLE and might reflect a state of active autoimmunity and fibrinolysis inhibition. Lupus (2018) 27, 139-142.
Introduction
Systemic lupus erythematosus (SLE) is a multifactorial, chronic autoimmune disorder characterized by the deposition of immune complexes in different organs that may lead to multisystem involvement. 1 It has a progressive as well as relapsingremitting nature in many patients. To properly follow up and treat patients, identification of variables predictive of organ involvement and outcome are of great importance. The autoantibody profile can be used as an important prognostic indicator for the treating physician. However, the different autoantibodies show their own specificities, which raise questions as to their prevalence, their association with the clinical manifestations, and their predictive significance for the evolution of the disease. a-enolase is a multifunctional protein that was first identified as a key component of the glycolytic pathway. a-enolase is usually located in the cytoplasm but can be expressed in the cell membrane of eukaryotic cells, including monocytes, T cells, B cells, neuronal cells, and endothelial cells, following inflammatory stimulus. 2 Upregulated surface expression of a-enolase may act as an autoantigen in the immune-related diseases. 3 Recently, Bruschi et al. identified a-enolase as a target antigen in the renal biopsy samples of patients with lupus nephritis (LN). 4 Moreover, a-enolase is a component of the complex extracellular trappings (NETs) that are released by neutrophils via an active process coined NETosis. Since NETosis is a major trigger of autoimmunity in lupus, externalization of a-enolase during lupus flares may lead to formation of circulating a-enolase antibody (Ab). 5 Consistent with this, several studies have shown that a-enolase Ab is positive in 20%-50% of SLE patients. 4 ,6,7 study, we analyzed the level of serum anti-a-enolase Ab in a cohort of patients with SLE, and evaluated its clinical significance by reviewing medical records and the results of laboratory tests. Informed consent was obtained from all individual participants included in the study. Clinical and laboratory data required to assess disease activity at the time of blood sampling were recorded. Sera from SLE patients and 20 healthy individuals, ageand sex-matched with the patients, were immediately frozen at À80 C to assay the level of Abs within one month. At the time of investigation, none of the patients or controls studied displayed evidence of infection, including past or current infection by hepatitis viruses or human immunodeficiency virus.
Methods

Participants
Detection of anti--enolase Ab
Enzyme-linked immunosorbent assay (ELISA) for anti-a-enolase Ab was performed using recombinant human a-enolase antigen (Sino Biological Inc, Beijing, China). A 96-well microtiter plate was coated overnight with 250 ng of recombinant human a-enolase antigen. The plate was washed three times with 0.05% phosphate-buffered salineTween 20 (PBST). Then, in each well, we added 100 ml of diluted serum from SLE patients and healthy controls, which was diluted 1:50 in PBST containing 1% bovine serum albumin (BSA, Sigma, St Louis, MO, USA) to block non-specific proteinbinding sites. The plate was incubated for two hours at room temperature. After washing the plate three times with PBST, we added 100 ml of secondary antibody conjugated to horseradish peroxydase, diluted at 1:5000 in blocking buffer immediately before use. Quantification of Ab binding was performed colorimetrically by addition of substrate (tetramethylbenzidine, Sigma) to each well. Optical density (OD) of the plates was read spectrophotometrically on an ELISA reader (Dynatech, Alexandria, VA, USA) at 450 nm.
Statistical methods
Categorical variables were compared using chisquared or Fisher's exact test, and continuous variables using Student's t-test, Mann-Whitney U test, or one-way analysis of variance (ANOVA). Pearson correlation test was used to examine the relationship between various laboratory measures and anti-a-enolase Ab level. A p value was set at < 0.05, two tailed. Analysis was performed using the SPSS 17.0 computer program.
Results
Clinical characteristics of SLE patients
A total of 32 SLE patients were enrolled in the present investigation. The mean age (standard deviation (SD)) of patients was 28.3 (9.5) years and the mean duration of disease was 3.6 (6.4) months. The clinical profile was characterized as shown in Table 1 . From our data, 59.4% patients had renal involvement at presentation (24-hour urine protein > 0.5 g or canal of red blood cells).
Level of serum anti--enolase Ab in SLE patients and healthy controls
Serum levels of anti-a-enolase Ab in SLE patients (n ¼ 32) and healthy controls (n ¼ 20) were (Figure 1(b) ). Patients with nephritis (n ¼ 19) displayed higher levels of anti-a-enolase Ab compared to those with musculoskeletal/cutaneous (n ¼ 22), neuro-psychiatric manifestations (n ¼ 4), serositis (n ¼ 7), and pneumonitis (n ¼ 5), but it was statistically insignificant. Furthermore, based on renal involvement all patients were categorized into two broad categories: (a) a nephritis group (n ¼ 19) and (b) a non-nephritis group (n ¼ 13). As shown in Figure 1 (c), patients with LN displayed significantly higher levels of anti-a-enolase Ab (OD value: 0.82 AE 0.19) compared to patients without renal involvement (0.66 AE 0.18, p ¼ 0.02).
Correlation between serum level of anti--enolase Ab and laboratory data
We further analyzed the correlation of serum antia-enolase Ab level and laboratory variables and systemic lupus erythematosus disease activity index (SLEDAI) scores. Table 2 shows the r and p values of the correlation analysis. We found these correlated positively with immunoglobulin (Ig)G and 24-hour urine protein, and negatively with D-dimer.
Discussion
In the present study, we observed elevated levels of serum anti-a-enolase Ab in untreated SLE patients. The serum level of anti-a-enolase Ab was relatively higher in the patients with LN, and positively correlated with 24-hour urine protein, suggesting that anti-a-enolase Ab may be involved in renal damage. This is in line with previous studies detecting anti-a-enolase Abs in patients with the autoimmune and inflammatory diseases involving the kidney. [8] [9] [10] Our results also showed that serum level of anti-a-enolase Ab positively correlated with the level of whole IgG. That means an elevated level of anti-a-enolase Ab may serve as a marker reflecting overproduction of various autoantibodies by dysfunctional plasma cells and B lymphocytes in active SLE.
Enolase also functions as the plasminogen receptor on the surface of various cells and plays 11 It has been suggested that citrullination of cell-surface a-enolase abrogates its plasminogen binding and activating function and contributes to the decreased fibrinolysis observed in rheumatoid arthritis. 12 In this study, we found that the SLE patients with a higher level of anti-aenolase Ab had a lower level of D-dimer. Because D-dimer is a main product of fibrin degradation, the reduction of D-dimer level indicated that the fibrinolysis was inhibited in some SLE patients. It has been demonstrated that a-enolase is responsible for the majority of the promotion of plasminogen activation on their surface, 13 and anti-a-enolase Abs isolated from the serum of patients with SLE or systemic scleroderma bound to the membraneassociated form of a-enolase, interfering with the plasminogen receptor function.
14 Thus, our results suggest that the SLE patients with anti-a-enolase Ab may have a higher risk of thrombosis. Future studies will be necessary to examine this possibility and explore the underlying molecular mechanism. Serum anti-a-enolase antibody in untreated SLE M Li et al.
